Annual CFO
-$18.09 M
-$733.90 K-4.23%
December 31, 2023
Summary
- As of February 7, 2025, IKT annual cash flow from operations is -$18.09 million, with the most recent change of -$733.90 thousand (-4.23%) on December 31, 2023.
- During the last 3 years, IKT annual CFO has fallen by -$16.96 million (-1501.29%).
- IKT annual CFO is now -2629.37% below its all-time high of $715.00 thousand, reached on December 31, 2018.
Performance
IKT Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$4.88 M
+$173.30 K+3.43%
September 30, 2024
Summary
- As of February 7, 2025, IKT quarterly cash flow from operations is -$4.88 million, with the most recent change of +$173.30 thousand (+3.43%) on September 30, 2024.
- Over the past year, IKT quarterly CFO has increased by +$173.30 thousand (+3.43%).
- IKT quarterly CFO is now -6565.03% below its all-time high of $75.50 thousand, reached on September 30, 2020.
Performance
IKT Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$17.24 M
-$776.00 K-4.71%
September 30, 2024
Summary
- As of February 7, 2025, IKT TTM cash flow from operations is -$17.24 million, with the most recent change of -$776.00 thousand (-4.71%) on September 30, 2024.
- Over the past year, IKT TTM CFO has dropped by -$776.00 thousand (-4.71%).
- IKT TTM CFO is now -9676.02% below its all-time high of -$176.40 thousand, reached on September 30, 2020.
Performance
IKT TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
IKT Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -4.2% | +3.4% | -4.7% |
| 3 y3 years | -1501.3% | +18.3% | +11.1% |
| 5 y5 years | -2629.4% | +18.3% | +11.1% |
IKT Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -26.5% | at low | -41.8% | +18.3% | -20.6% | +12.0% |
| 5 y | 5-year | -5245.9% | at low | -6565.0% | +18.3% | -9676.0% | +12.0% |
| alltime | all time | -2629.4% | at low | -6565.0% | +18.3% | -9676.0% | +12.0% |
Inhibikase Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$4.88 M(-3.4%) | -$17.24 M(+4.7%) |
| Jun 2024 | - | -$5.05 M(+30.7%) | -$16.47 M(+3.1%) |
| Mar 2024 | - | -$3.87 M(+12.3%) | -$15.98 M(-11.6%) |
| Dec 2023 | -$18.09 M(+4.2%) | -$3.44 M(-16.1%) | -$18.09 M(-0.6%) |
| Sep 2023 | - | -$4.11 M(-10.1%) | -$18.20 M(-7.1%) |
| Jun 2023 | - | -$4.57 M(-23.6%) | -$19.60 M(+1.1%) |
| Mar 2023 | - | -$5.97 M(+67.9%) | -$19.39 M(+11.7%) |
| Dec 2022 | -$17.35 M(+21.4%) | -$3.56 M(-35.4%) | -$17.35 M(-3.0%) |
| Sep 2022 | - | -$5.50 M(+26.4%) | -$17.89 M(+24.2%) |
| Jun 2022 | - | -$4.36 M(+10.7%) | -$14.41 M(+0.8%) |
| Mar 2022 | - | -$3.93 M(-3.9%) | -$14.30 M(0.0%) |
| Dec 2021 | -$14.30 M | -$4.10 M(+102.7%) | -$14.30 M(+28.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$2.02 M(-52.4%) | -$11.15 M(+23.2%) |
| Jun 2021 | - | -$4.25 M(+7.9%) | -$9.05 M(+88.3%) |
| Mar 2021 | - | -$3.93 M(+315.7%) | -$4.81 M(+325.8%) |
| Dec 2020 | -$1.13 M(+233.8%) | -$946.50 K(-1353.6%) | -$1.13 M(+540.2%) |
| Sep 2020 | - | $75.50 K(-2703.4%) | -$176.40 K(-31.8%) |
| Jun 2020 | - | -$2900.00(-98.9%) | -$258.70 K(-15.2%) |
| Mar 2020 | - | -$255.40 K(-4090.6%) | -$304.90 K(-9.8%) |
| Dec 2019 | -$338.30 K(-147.3%) | $6400.00(-194.1%) | -$338.20 K(-1.9%) |
| Sep 2019 | - | -$6800.00(-86.2%) | -$344.60 K(+2.0%) |
| Jun 2019 | - | -$49.10 K(-83.0%) | -$337.80 K(+17.0%) |
| Mar 2019 | - | -$288.70 K | -$288.70 K |
| Dec 2018 | $715.00 K | - | - |
FAQ
- What is Inhibikase Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual CFO year-on-year change?
- What is Inhibikase Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly CFO year-on-year change?
- What is Inhibikase Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics TTM CFO year-on-year change?
What is Inhibikase Therapeutics annual cash flow from operations?
The current annual CFO of IKT is -$18.09 M
What is the all time high annual CFO for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual cash flow from operations is $715.00 K
What is Inhibikase Therapeutics annual CFO year-on-year change?
Over the past year, IKT annual cash flow from operations has changed by -$733.90 K (-4.23%)
What is Inhibikase Therapeutics quarterly cash flow from operations?
The current quarterly CFO of IKT is -$4.88 M
What is the all time high quarterly CFO for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly cash flow from operations is $75.50 K
What is Inhibikase Therapeutics quarterly CFO year-on-year change?
Over the past year, IKT quarterly cash flow from operations has changed by +$173.30 K (+3.43%)
What is Inhibikase Therapeutics TTM cash flow from operations?
The current TTM CFO of IKT is -$17.24 M
What is the all time high TTM CFO for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high TTM cash flow from operations is -$176.40 K
What is Inhibikase Therapeutics TTM CFO year-on-year change?
Over the past year, IKT TTM cash flow from operations has changed by -$776.00 K (-4.71%)